Chiesi gains commercialization rights to uniQure's Glybera

07/11/2013 | Pharmaceutical Business Review Online

Chiesi Farmaceutici secured exclusive rights to market uniQure's Glybera, the first gene therapy approved in Europe, for treatment of lipoprotein lipase deficiency. Chiesi and uniQure also agreed to jointly develop a hemophilia B gene therapy. UniQure will get 20% to 30% of net royalties on sales of both drugs.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT